Stockreport

Immunome to Present Preclinical Data for IM-3050, Its Lead Radioligand Therapy Candidate, at 2024 American Association for Cancer Research (AACR) Annual Meeting [Yahoo! Finance]

Immunome, Inc.  (IMNM) 
PDF best-in-class targeted cancer therapies, today announced that it will present preclinical data for IM-3050, the company's lead lutetium-177 radioligand therapy (RLT) tar [Read more]